Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POMALIDOMIDE vs ADDERALL 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.
Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.
Multiple myeloma, relapsed or refractory (in combination with dexamethasone),Multiple myeloma, maintenance therapy post-autologous stem cell transplant,AIDS-related Kaposi sarcoma (off-label),Primary effusion lymphoma (off-label)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.
10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.
Terminal half-life approximately 7.5 hours in patients with normal renal function; prolonged to 9-12 hours in moderate renal impairment.
Terminal elimination half-life: dextroamphetamine 9-11 hours, levoamphetamine 11-14 hours (Adderall is a mixed salt). In adults, mean half-life ~10 hours; in children, slightly shorter (6-8 hours). Clinical context: steady-state reached in 2-3 days; dosing interval typically 4-6 hours for immediate-release.
Primarily metabolized by CYP1A2 and CYP3A4; undergoes glucuronidation via UGT1A8.
Amphetamine is metabolized primarily in the liver via cytochrome P450 enzymes, including CYP2D6, and undergoes deamination and oxidation to form inactive metabolites including 4-hydroxyamphetamine and norephedrine.
Renal (73% as unchanged drug and metabolites), fecal (15%), biliary (minimal).
Renal: 70-80% (30-40% as unchanged amphetamine; remainder as deaminated and hydroxylated metabolites). Fecal: minimal (<5%). Biliary: negligible. Urinary p H affects excretion: acidic urine increases elimination, alkaline urine decreases.
12-44% bound to albumin and alpha-1-acid glycoprotein; mean ~30%.
Amphetamine: 15-40% bound to plasma proteins (primarily albumin). Binding is not extensive, thus significant free fraction available for distribution.
62-138 L (approx 0.8-1.7 L/kg); indicates extensive tissue distribution.
Apparent Vd: 3.0-4.0 L/kg (for total amphetamine). High Vd indicates extensive tissue distribution, including brain. Clinical meaning: loading dose may be needed for rapid effect; distribution half-life ~1 hour.
Oral: 73% (range 56-85%); high fat meal reduces AUC by 13% but no significant effect.
Oral immediate-release: 100% (well-absorbed; first-pass metabolism minimal). Food delays absorption but does not affect extent. Extended-release: bioavailability similar to immediate-release with modified release profile.
Cr Cl 30-59 m L/min: 3 mg once daily. Cr Cl <30 m L/min: 2 mg once daily. Not recommended if Cr Cl <15 m L/min or requiring dialysis.
e GFR 15-29 m L/min: reduce dose by 50% and monitor for toxicity; e GFR <15 m L/min or dialysis: avoid use due to risk of accumulation; consider alternative therapy.
Child-Pugh A: 4 mg once daily. Child-Pugh B: 2 mg once daily. Child-Pugh C: 1 mg once daily.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to decreased clearance and increased risk of toxicity.
Safety and efficacy not established; no recommended dosing.
Children 3-5 years: 2.5 mg orally once daily; may increase by 2.5 mg weekly; usual range 2.5-20 mg/day divided 1-2 times. Children 6 years and older: initial 5 mg once daily; may increase by 5 mg weekly; usual range 5-40 mg/day divided 1-3 times; maximum 40 mg/day.
No specific dose adjustment; monitor for increased toxicity (e.g., myelosuppression, neurotoxicity) due to age-related organ function decline.
Initiate at 2.5-5 mg orally once daily; titrate slowly in increments of 2.5-5 mg weekly; monitor for cardiovascular effects, insomnia, and weight loss; maximum 40 mg/day.
WARNING: EMBRYO-FETAL TOXICITY, VENOUS AND ARTERIAL THROMBOEMBOLISM, HEPATOTOXICITY, and INCREASED MORTALITY IN MULTIPLE MYELOMA. Pomalidomide is contraindicated in pregnant women due to teratogenicity. Thromboembolic events (DVT, PE, MI, stroke) are increased. Hepatotoxicity may be severe. In multiple myeloma clinical trials, pomalidomide/dexamethasone was associated with increased mortality in patients with high-risk cytogenetics (del 17p, t(4;14), t(14;16)).
Potential for abuse and dependence. Amphetamines have a high potential for abuse, which may lead to dependence and serious cardiovascular adverse events. Misuse may cause sudden death and serious cardiovascular events.
Embryo-fetal toxicity (must use contraception); venous/arterial thromboembolism (consider prophylaxis); hepatotoxicity (monitor LFTs); increased mortality in high-risk multiple myeloma; hematologic toxicity (neutropenia, thrombocytopenia); cardiac toxicity (arrhythmias, heart failure); severe cutaneous reactions; tumor lysis syndrome; renal impairment; fetal risk during pregnancy; avoid use in patients with prior hypersensitivity to thalidomide analogs.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase; caution in hypertension and other cardiovascular conditions.,Psychiatric adverse events including exacerbation of psychosis, mania, and aggression.,Long-term suppression of growth in pediatric patients.,Peripheral vasculopathy including Raynaud's phenomenon.,Seizures: may lower seizure threshold.,Serotonin syndrome risk when co-administered with serotonergic drugs.
Pregnancy (absolute); women of childbearing potential not using effective contraception; men not using condoms during sexual activity with pregnant or non-pregnant women; hypersensitivity to pomalidomide or thalidomide analogs; prior severe dermatologic reactions to pomalidomide.
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity or idiosyncrasy to sympathomimetic amines,Glaucoma,Agitated states,History of drug abuse,During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may occur)
Avoid grapefruit juice and grapefruit products. Take with water, not with food to reduce nausea.
High-fat meals can delay absorption; avoid acidic foods (e.g., citrus, cola) within 1 hour of dosing as they decrease absorption. Avoid caffeine; may increase stimulant effects.
First trimester: High risk of severe birth defects (e.g., limb anomalies, neural tube defects) due to potent teratogenicity; absolutely contraindicated. Second/third trimester: Risk of fetal harm persists; no safe level established; discontinue if possible.
Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimesters: risk of fetal growth restriction, preterm delivery, and neonatal withdrawal symptoms (irritability, poor feeding).
No data on M/P ratio; excreted in animal milk; potential for serious adverse reactions in infant; breastfeeding contraindicated during therapy and for at least 7 days after last dose.
Excreted into breast milk; relative infant dose estimated at 2-4% of maternal weight-adjusted dose. M/P ratio not well established. Manufacturer recommends caution; potential for infant agitation, insomnia, and growth suppression.
No specific dose adjustments in pregnancy due to contraindication; pharmacokinetic changes (e.g., increased clearance) theoretically require higher doses if used, but teratogenicity prohibits use; avoid exposure entirely.
Increased plasma volume and enhanced hepatic metabolism may reduce amphetamine levels; dose adjustments should be individualized based on clinical response, but controlled studies lacking. Avoid abrupt discontinuation due to risk of withdrawal symptoms in mother and neonate.
Thromboprophylaxis with aspirin or low molecular weight heparin is mandatory due to high VTE risk. Monitor CBC and thyroid function monthly. Contraindicated in pregnancy due to teratogenicity. Pomalidomide requires REMS program enrollment. Dose reduction needed for renal impairment (Cr Cl <45 m L/min).
Adderall 10 mg contains immediate-release amphetamine salts. Onset of action is 30-60 minutes, duration 4-6 hours. Monitor for appetite suppression, insomnia, and cardiovascular effects. Avoid in patients with structural cardiac abnormalities or history of substance abuse. Use with caution in hypertension or hyperthyroidism. Drug holidays may reduce tolerance.
Do not become pregnant while taking this drug; use two reliable forms of contraception.,Report any signs of bleeding or bruising, as pomalidomide can cause low platelet counts.,Avoid grapefruit and grapefruit juice as they may increase drug levels.,Take capsules whole, not crushed or chewed, with water.,Do not donate blood during treatment and for 4 weeks after stopping.
Take exactly as prescribed; do not crush or chew tablets.,Take early in the day to prevent insomnia.,May cause weight loss; monitor growth in children.,Avoid alcohol and decongestants (risk of hypertensive crisis).,Report chest pain, palpitations, or shortness of breath immediately.,Do not drive if you feel dizzy or impaired.
"Dextropropoxyphene, an opioid analgesic, and pomalidomide, an immunomodulatory agent, both pose risks of QT interval prolongation. Co-administration may result in additive QT prolongation, increasing the risk of torsade de pointes, a potentially fatal ventricular arrhythmia. Additionally, dextropropoxyphene may exacerbate the sedative and respiratory depressant effects of pomalidomide, leading to excessive central nervous system depression."
"Concomitant use of pomalidomide and perampanel may result in additive central nervous system (CNS) depression due to their independent sedative properties. Pomalidomide, an immunomodulatory drug, is associated with somnolence and fatigue, while perampanel, an AMPA receptor antagonist, commonly causes dizziness, somnolence, and ataxia. This combination can lead to excessive sedation, impaired cognitive function, and increased risk of falls or accidents, particularly in elderly patients or those with impaired hepatic function."
"The concurrent use of desflurane, a halogenated inhalational anesthetic, with pomalidomide, an immunomodulatory agent, may potentiate the risk of severe hypotension and bradycardia due to additive cardiovascular depression. Desflurane directly depresses myocardial contractility and systemic vascular resistance, while pomalidomide can induce vasodilation and negative chronotropic effects. Clinically, patients may experience profound drops in blood pressure and heart rate, leading to reduced cardiac output and potential end-organ hypoperfusion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POMALIDOMIDE vs ADDERALL 10, answered by our medical review team.
POMALIDOMIDE is a Immunomodulatory Agent that works by Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.. ADDERALL 10 is a CNS Stimulant that works by Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POMALIDOMIDE and ADDERALL 10 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POMALIDOMIDE is: 4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.. The standard adult dose of ADDERALL 10 is: 10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POMALIDOMIDE and ADDERALL 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POMALIDOMIDE is classified as Category C. First trimester: High risk of severe birth defects (e.g., limb anomalies, neural tube defects) due to potent teratogenicity; absolutely contraindicated. Second/third trimester: Ris. ADDERALL 10 is classified as Category C. Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.